PureTech Health plc (LON:PRTC – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The company traded as low as GBX 138.75 ($1.86) and last traded at GBX 140.10 ($1.87), with a volume of 855201 shares traded. The stock had previously closed at GBX 141.40 ($1.89).
PureTech Health Stock Performance
The company has a debt-to-equity ratio of 47.27, a current ratio of 3.68 and a quick ratio of 2.51. The company has a 50 day simple moving average of GBX 160.42 and a 200-day simple moving average of GBX 193.20. The firm has a market cap of £335.43 million, a PE ratio of -609.14 and a beta of 1.02.
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More
- Five stocks we like better than PureTech Health
- Best Stocks Under $5.00
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Technology Stocks Explained: Here’s What to Know About Tech
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
